Abstract: The invention provides a modified T cell, or an isolated population of immune cells expressing a CXCR3 isoform selected from CXCR3A, CXCR3B, and CXCR3alt, and optionally, further expressing transgenes comprising an artificial T cell receptor, and/or a CXCR3 ligand, for use as a medicament. The invention also provides the methods to obtain said cells, or populations of cells from a plurality of immune cells derived from a human subject. The invention also relates to assessment of CXCR3 splice variants and its ligands CXCL9, CXCL10, and CXCL11 in muscle-invasive bladder cancer (MIBC) patients, to enable patients to be stratified for their predicted response to a chemotherapy drug treatment, or clinical outcome.

Abstract: It is provided a system for magnetic stimulation of biological tissue, comprising at least two magnetic field generating devices for generating time-varying magnetic fields, wherein the magnetic field generating devices are to be arranged relative to the tissue in such a way that their time-varying magnetic fields at least partially overlap in the tissue; and at least one controlling arrangement for controlling the two magnetic field generating devices (D1-D4). The controlling arrangement is configured to control at least one of the two magnetic field generating devices in such a way that the time-varying magnetic field generated by the at least one device is phase modulated.

Abstract: The invention relates to a sample holder assembly (1) for microscopy comprising at least the following components: A first member (10) having a first opening (14) on a first side of the first member (10), and a circumferential wall portion (12) having an inward facing side (12-1) that faces toward the first volume (V1) and an outward facing side (12-2) opposite the inward facing side (12-1); A second member (20) having a first opening (24) at a first side of the second member (20), and a circumferential wall portion (22) having an inward facing side (22-1) facing toward the second volume (V2), wherein a shape of the outward facing side (12-2) of the wall portion (12) of the first member (10) is complementary to the inward facing side (22-1) of the wall portion (22) of the second member (20), such that the wall portion (12) of the first member (10) can be inserted in the second volume (V2), such that the first volume (V1) is at least partially comprised by the second volume (V2); A transparent membrane (30) ha

Abstract: The invention relates to a saponin derivative based on a saponin comprising a triterpene aglycone and a first saccharide chain and/or a second saccharide chain, and comprising: an aglycone core structure comprising an aldehyde group which has been derivatised; and/or the first saccharide chain wherein the first saccharide chain comprises a carboxyl group, which has been derivatised; and/or the second saccharide chain wherein the second saccharide chain comprises at least one acetoxy group which has been derivatised. The invention also relates to a first pharmaceutical composition comprising the saponin derivative of the invention.

Abstract: Provided herein is a method for predicting the probability of having or developing a non-fusion, wherein said method comprises determining the frequency of a subpopulation of CD8+ T cells selected from CD8+CD57+, CD8+CD28? and CD8+CD57+CD28? in a sample obtained from a patient. Also provided herein is a system for predicting the probability of having or developing a non-fusion.

Abstract: A process is provided in which the resulting Fe-tCDTA contrast agent has a reduced osmolality. The process according to the invention comprises the following steps: a) preparing an aqueous solution of tCDTA and FeO(OH), tCDTA and FeO(OH) being present in a molar ratio of from 1:1 to 1:1.4; b) b.1) adjusting a pH of the aqueous solution to between pH 2.5 and pH 4.5 by adding a base, preferably meglumine, and separating the precipitate; or b.2) precipitating the Fe-tCDTA contrast agent from the aqueous solution by adding acetone, separating the precipitate, and preparing an aqueous solution from the precipitate; and c) adjusting a pH of the aqueous solution to between pH 6.5 and pH 8.0 by adding a base, preferably meglumine, and separating the precipitated FeO(OH).

Abstract: The invention relates to a method and a computer program for estimating shape parameters of an image data set (1) of a fovea (100), comprising the steps of: Acquiring an image data set (1) of a macula (50), comprising a foveal pit (101) and a foveal rim (102) at least partially, Estimating the center of the foveal pit (101) from the image data set (1), Estimating from the center of the foveal pit (101), radially extending height profiles (c) of the fovea (100), For each height profile (c), fitting a model-function to the height profile (c), Estimating for each height profile (c) a set of fit parameters from the fitted model-function, Determining from the sets of estimated fit parameters at least one shape parameter of the fovea (100), particularly of the foveal pit (101). Determining at least one shape feature of at least a part of the fovea.

Abstract: The invention concerns a medical device for at least periodical contact with diseased vessels such as a stent or a balloon catheter, for example, as well as a method for coating it with a defined solution. In accordance with the invention, a restenosis inhibitor is disposed on an outer surface in an active substance concentration of more than 4 ?g/mm2.

Abstract: A microscope system (100) configured to record images in at least a first and a second imaging mode (501, 502), comprising: An objective (1) collecting light (201) from a sample (11), An illumination module coupled to the objective, A first reimaging objective (5) generating an intermediate image of the sample and a second reimaging objective (6) that relays the intermediate image onto a detection module, An evaluation module (200) comprising a machine learning method (DL), trained with a first and a second set of images of the same sample, wherein the first and second set has been acquired in the first (501) and second imaging mode (502), respectively, wherein upon acquisition of an image (400) in the second imaging mode (502) the trained machine learning method (DL) outputs a restored image (401) that comprises fewer aberrations than the image (400) acquired in the second imaging mode (52, 53, 57).

Abstract: The present invention relates to a method for diagnosis of delayed bone fracture healing, comprising determining the frequency of a subpopulation of CD8+ cells selected from a first group comprised of CD8+CD57+, CD8+CD28? and CD8+CD28?/CD57+, in a sample obtained from a subject. The present invention further relates to a system and a kit of parts for prediction and resulting options for preventing of delayed bone fracture healing.

Abstract: A biomaterial, particularly for tissue regeneration, includes an open, porous bioresorbable first material portion and a second material portion that is stiffer than the first material portion, wherein the volume fraction of the stiffer material is less than 30% of the total volume of the biomaterial, and the structural stiffness of the second material portion is at least 10 times greater than that of the first material portion.

Abstract: It is provided a method of treatment of a human or animal patient in need thereof to achieve a reduction of the viscosity of mucus of the patient which is carried out by administering a polyglycerol derivative having a linear or dendritic polyglycerol backbone and carrying at least one thiol group covalently bound to the polyglycerol backbone. It is further provided a method of treatment of a human or animal patient suffering from chronic sinusitis, asthma, chronic bronchitis, cystic fibrosis, chronic obstructive pulmonary disease, emphysema, bronchiectasis, chronic inflammatory bowel diseases, constipation, gastrointestinal malabsorption syndrome, irritable bowel syndrome, steatorrhea or diarrhea by administering a polyglycerol derivative. Further specific thiol-functionalized polyglycerol derivatives and a corresponding manufacturing method are provided.

Abstract: The invention relates to a device and a method for UV antisepsis, in particular for intracorporeal in vivo UV antisepsis on the human and animal body in the event of colonization with multiresistant pathogens (MRPs) such as methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus epidermidis (MRSE). The device comprises a light emitting diode chip, LED chip, configured to emit radiation in the UVC spectral range, wherein the LED chip forms a light emitting diode, LED, with a package; a spectral filter element set up to limit the radiation emitted by the LED chip substantially to wavelengths below 235 nm; and an optical element for directional emission of the radiation emitted by the LED.

Abstract: The invention relates to a ligand-effector moiety provided with at least one saponin and antibody-effector moiety provided with at least one saponin. An aspect of the invention is a composition comprising the ligand-effector moiety provided with at least one saponin or the antibody-effector moiety provided with at least one saponin of the invention. The invention also relates to an antibody-drug conjugate comprising covalently linked saponin and to an antibody-oligonucleotide conjugate comprising covalently linked saponin. An aspect of the invention relates to a pharmaceutical composition comprising the ligand-effector moiety provided with at least one saponin or the antibody-effector moiety provided with at least one saponin of the invention, and optionally further comprising a pharmaceutically acceptable excipient. The invention also relates to the ligand-effector moiety provided with at least one saponin or the antibody-effector moiety provided with at least one saponin, for use as a medicament.

Abstract: The invention relates to an endosomal and/or lysosomal escape enhancing conjugate comprising a saponin optionally linked to a targeting molecule such as an antibody and optionally linked to an effector molecule such as a toxin or an oligonucleotide. The invention also relates to a therapeutic combination of such an endosomal and/or lysosomal escape enhancing conjugate of the invention and a functionalized binding molecule comprising an effector molecule, wherein the endosomal and/or lysosomal escape enhancing conjugate comprises an enhancer of said effector molecule, i.e. a saponin. In particular the invention relates to such a therapeutic combination for use as a medicament, in particular for use in the treatment of a tumour.

Abstract: The invention relates to antibody-drug conjugates (ADC) that are potentiated by co-administration of the ADC with a moiety comprising covalently linked saponin. The invention also relates to antibody-oligonucleotide conjugates (AOC) that are potentiated by co-administration of the AOC with a moiety comprising covalently linked saponin. The invention also relates to ADCs and AOCs which are conjugated with a saponin via a covalent linker. The invention further relates to an effector moiety such as a toxin or an antisense oligonucleotide such as for example a BNA, conjugated with a saponin via a covalent linkage. The invention also relates to a BNA covalently conjugated with a targeting moiety such as an antibody.

Abstract: The invention relates to an in vitro method for determining the severity or a grade of a human papillomavirus (HPV)-induced dysplasia or whether cervical carcinoma is present, and related materials, devices and computer-implementation of the method. The present invention comprises quantitatively determining an expression level of (i) viral and (ii) cellular messenger RNA (mRNA) in a sample obtained from the subject, wherein the determined viral mRNA encodes an HPV oncoprotein E6 and/or E7, and wherein the determined cellular mRNA comprises mRNA of at least one cellular proliferation marker, of at least one cancer stem cell marker, and of at least one tumor marker, and deducing from the quantity of said viral mRNA and said cellular mRNA the severity or a grade of the dysplasia or whether cervical carcinoma is present in the subject.

Abstract: The invention relates to a therapeutic combination, comprising a first proteinaceous molecule comprising a first binding site for binding to a first epitope of a first cell-surface molecule, the first proteinaceous molecule provided with at least one saponin covalently bound to an amino-acid residue of said first proteinaceous molecule, and comprising a second pharmaceutical composition comprising a second proteinaceous molecule different from the first proteinaceous molecule, the second proteinaceous molecule comprising a second binding site for binding to a second epitope of a second cell-surface molecule different from the first cell-surface molecule, and comprising an effector moiety, wherein the second epitope is different from the first epitope. An aspect of the invention is a composition comprising the first proteinaceous molecule and the second proteinaceous molecule of the invention.

Abstract: The invention relates to a molecular scaffold suitable for covalently binding at least one biologically active molecule to a carrier molecule, the scaffold comprising a polymeric structure and the biologically active molecules covalently bound to said polymeric structure, and wherein the scaffold further comprises a chemical group for covalently coupling of the scaffold to the carrier molecule. The biologically active molecule has a molecular weight of 3.000 Dalton or less, such as 1.700 Dalton-1.950 Dalton. The biologically active molecule is an amphiphilic molecule in some embodiments. The biologically active molecule is a single specific molecule or is a mixture of different types of molecules, when more than one biologically active molecules are covalently bound to the polymeric (or oligomeric) structure. In particular, the invention relates to monoclonal antibody-based antibody-drug conjugates with improved therapeutic window of the drug due to covalent linkage of (a cluster of) potentiator molecules, e.

Abstract: The invention relates to a therapeutic combination, comprising a first proteinaceous molecule comprising a first binding site for binding to a first epitope of a first cell-surface molecule, the first proteinaceous molecule provided with at least one saponin covalently bound to an amino-acid residue of said first proteinaceous molecule, and comprising a second pharmaceutical composition comprising a second proteinaceous molecule different from the first proteinaceous molecule, the second proteinaceous molecule comprising a second binding site for binding to a second epitope of a second cell-surface molecule different from the first cell-surface molecule, and comprising an effector moiety, wherein the second epitope is different from the first epitope. An aspect of the invention is a composition comprising the first proteinaceous molecule and the second proteinaceous molecule of the invention.